vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Axos Financial, Inc. is the larger business by last-quarter revenue ($392.2M vs $177.4M, roughly 2.2× Pacira BioSciences, Inc.). Axos Financial, Inc. runs the higher net margin — 31.8% vs 1.6%, a 30.1% gap on every dollar of revenue. Over the past eight quarters, Axos Financial, Inc.'s revenue compounded faster (16.1% CAGR vs -0.2%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AX vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $177.4M |
| Net Profit | $124.7M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 31.8% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | 18.5% | — |
| EPS (diluted) | $2.15 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | $177.4M | ||
| Q4 25 | $385.1M | $196.9M | ||
| Q3 25 | $323.4M | $179.5M | ||
| Q2 25 | $321.4M | $181.1M | ||
| Q1 25 | $308.8M | $168.9M | ||
| Q4 24 | $307.9M | $187.3M | ||
| Q3 24 | $320.7M | $168.6M | ||
| Q2 24 | $290.9M | $178.0M |
| Q1 26 | $124.7M | $2.9M | ||
| Q4 25 | $128.4M | — | ||
| Q3 25 | $112.4M | $5.4M | ||
| Q2 25 | $110.7M | $-4.8M | ||
| Q1 25 | $105.2M | $4.8M | ||
| Q4 24 | $104.7M | — | ||
| Q3 24 | $112.3M | $-143.5M | ||
| Q2 24 | $104.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 45.6% | 1.2% | ||
| Q3 25 | 46.3% | 3.5% | ||
| Q2 25 | 48.5% | 4.7% | ||
| Q1 25 | 47.9% | 1.2% | ||
| Q4 24 | 48.8% | 13.2% | ||
| Q3 24 | 49.6% | -82.8% | ||
| Q2 24 | 49.6% | 15.9% |
| Q1 26 | 31.8% | 1.6% | ||
| Q4 25 | 33.3% | — | ||
| Q3 25 | 34.7% | 3.0% | ||
| Q2 25 | 34.4% | -2.7% | ||
| Q1 25 | 34.1% | 2.8% | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 35.0% | -85.1% | ||
| Q2 24 | 36.0% | 10.6% |
| Q1 26 | $2.15 | $0.07 | ||
| Q4 25 | $2.22 | $0.05 | ||
| Q3 25 | $1.94 | $0.12 | ||
| Q2 25 | $1.89 | $-0.11 | ||
| Q1 25 | $1.81 | $0.10 | ||
| Q4 24 | $1.80 | $0.38 | ||
| Q3 24 | $1.93 | $-3.11 | ||
| Q2 24 | $1.75 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.1B | $653.9M |
| Total Assets | $29.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $1.0B | $238.4M | ||
| Q3 25 | $2.6B | $246.3M | ||
| Q2 25 | $1.9B | $445.9M | ||
| Q1 25 | $2.0B | $493.6M | ||
| Q4 24 | $2.4B | $484.6M | ||
| Q3 24 | $2.6B | $453.8M | ||
| Q2 24 | $2.0B | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | $312.7M | $580.5M | ||
| Q1 25 | $377.4M | $583.4M | ||
| Q4 24 | $358.7M | $585.3M | ||
| Q3 24 | $313.5M | — | ||
| Q2 24 | $325.7M | — |
| Q1 26 | $3.1B | $653.9M | ||
| Q4 25 | $2.9B | $693.1M | ||
| Q3 25 | $2.8B | $727.2M | ||
| Q2 25 | $2.7B | $757.8M | ||
| Q1 25 | $2.6B | $798.5M | ||
| Q4 24 | $2.5B | $778.3M | ||
| Q3 24 | $2.4B | $749.6M | ||
| Q2 24 | $2.3B | $879.3M |
| Q1 26 | $29.2B | $1.2B | ||
| Q4 25 | $28.2B | $1.3B | ||
| Q3 25 | $27.4B | $1.3B | ||
| Q2 25 | $24.8B | $1.5B | ||
| Q1 25 | $24.0B | $1.6B | ||
| Q4 24 | $23.7B | $1.6B | ||
| Q3 24 | $23.6B | $1.5B | ||
| Q2 24 | $22.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | 0.12× | 0.77× | ||
| Q1 25 | 0.14× | 0.73× | ||
| Q4 24 | 0.14× | 0.75× | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
